Galapagos (NASDAQ:GLPG - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
Galapagos Stock Down 0.9 %
Shares of NASDAQ:GLPG traded down $0.26 during trading on Wednesday, hitting $29.98. 109,098 shares of the company were exchanged, compared to its average volume of 130,944. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46. The business's 50 day moving average is $28.78 and its 200-day moving average is $27.84.
Wall Street Analyst Weigh In
GLPG has been the topic of several research reports. Raymond James cut Galapagos from an "outperform" rating to a "market perform" rating in a report on Friday, August 2nd. Leerink Partners initiated coverage on Galapagos in a research report on Monday, September 9th. They issued a "market perform" rating and a $24.00 price target on the stock. Finally, Leerink Partnrs upgraded Galapagos to a "hold" rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat, Galapagos presently has a consensus rating of "Hold" and an average target price of $31.00.
View Our Latest Report on GLPG
Galapagos Company Profile
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Recommended Stories
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
